UniQure Revenue 2013-2021 | QURE

UniQure revenue from 2013 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
UniQure Annual Revenue
(Millions of US $)
2020 $38
2019 $7
2018 $11
2017 $13
2016 $25
2015 $11
2014 $6
2013 $4
2012 $
UniQure Quarterly Revenue
(Millions of US $)
2021-09-30 $2
2021-06-30 $464
2021-03-31 $0
2020-12-31 $34
2020-09-30 $2
2020-06-30 $2
2020-03-31 $0
2019-12-31 $3
2019-09-30 $1
2019-06-30 $2
2019-03-31 $1
2018-12-31 $2
2018-09-30 $3
2018-06-30 $3
2018-03-31 $3
2017-12-31 $3
2017-09-30 $2
2017-06-30 $5
2017-03-31 $3
2016-12-31 $9
2016-09-30 $7
2016-06-30 $4
2016-03-31 $4
2015-12-31 $4
2015-09-30 $4
2015-06-30 $2
2015-03-31 $1
2014-12-31 $2
2014-09-30 $1
2014-06-30 $1
2014-03-31 $2
2013-12-31
2013-09-30
2012-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.844B $0.038B
UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00